VAXART INC. - COMMON STOCK

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19 نوفمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

13 نوفمبر 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13

07 نوفمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024

24 أكتوبر 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need

15 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

30 سبتمبر 2024 15:12:22 بحسب Nasdaq GlobeNewswire

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia

28 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

08 أغسطس 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8

02 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Vaxart Provides Business Update

17 يونيو 2024 15:05:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: VAXART INC. - COMMON STOCK

17 يونيو 2024 14:51:57 بحسب NetDania Notify

Vaxart Announces $40 Million Underwritten Offering of Common Stock

13 يونيو 2024 18:07:26 بحسب Nasdaq GlobeNewswire

Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

13 يونيو 2024 15:15:11 بحسب Nasdaq GlobeNewswire

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

23 مايو 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results

13 مايو 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13

07 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

30 أبريل 2024 07:00:39 بحسب Nasdaq GlobeNewswire

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

27 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

20 مارس 2024 07:00:13 بحسب Nasdaq GlobeNewswire